Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Ticker
$OGN
Sector
Primary listing
NYSE
Employees
10,000
Headquarters
Website
Organon Metrics
BasicAdvanced
$2.4B
3.45
$2.69
0.56
$0.86
0.86%
Price and volume
Market cap
$2.4B
Beta
0.56
52-week high
$23.10
52-week low
$8.01
Average daily volume
4.4M
Dividend rate
$0.86
Financial strength
Current ratio
1.652
Quick ratio
0.755
Long term debt to equity
1,197.954
Total debt to equity
1,213.643
Dividend payout ratio (TTM)
32.71%
Interest coverage (TTM)
2.65%
Profitability
EBITDA (TTM)
1,677
Gross margin (TTM)
56.57%
Net profit margin (TTM)
11.14%
Operating margin (TTM)
21.62%
Effective tax rate (TTM)
-5.11%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
6.62%
Return on equity (TTM)
159.64%
Valuation
Price to earnings (TTM)
3.452
Price to revenue (TTM)
0.382
Price to book
3.29
Price to tangible book (TTM)
-0.45
Price to free cash flow (TTM)
4.972
Free cash flow yield (TTM)
20.11%
Free cash flow per share (TTM)
1.866
Dividend yield (TTM)
9.27%
Forward dividend yield
0.86%
Growth
Revenue change (TTM)
-1.02%
Earnings per share change (TTM)
-30.66%
3-year revenue growth (CAGR)
-0.39%
3-year earnings per share growth (CAGR)
-14.77%
3-year dividend per share growth (CAGR)
-8.43%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Organon News
AllArticlesVideos
Organon Reports Results for the Second Quarter Ended June 30, 2025
Business Wire·3 weeks ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Business Wire·1 month ago
Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept11
Organon
Dividend·Payment
$0.02Per share
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $2.4B as of August 23, 2025.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 3.45 as of August 23, 2025.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of August 23, 2025, the dividend rate is $0.86 and the yield is 0.86%. Organon has a payout ratio of 32.71% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment is scheduled for September 11, 2025.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.